| ID | 1515 | |
| PMID | 16123410 | |
| Year | 2005 | |
| Sequence | SSSHPIFHRGEFSVCD SVSVWVGDKTTATDIK GKEVMVLGEVNINNSV FKQYFFETKCRDPNPV DSGCRGIDSKHWNSYC TTTHTFVKALTMDGKQ AAWRFIRIDTACVCVL SRKAVRRA | |
| Name | Nerve Growth Factor | |
| Length | 120 | |
| N-Terminal Modification | Free | |
| C-Terminal Modification | Free | |
| Linear/ Cyclic | Cyclic (C15-C80, C58-C108,C68-C110) | |
| Chirality | L | |
| Chemical Modification | None | |
| Origin of Peptide | Keratocytes and epithelial and endothelial cells synthesize NGF. | |
| Nature of Peptide/Cargo | Neurotrophic and immunomodulatory mediator responsible for the growth, differentiation, and survival of sensory neurons and acceleration of wound healing | |
| Mechanism | Not mentioned | |
| Cargo Sequence/Structure | C22H32O2 | |
| Name of cargo | Not applicable | |
| Assay | Immunostaining | |
| Enhancer | Not applicable | |
| Properties of enhancer | Not mentioned | |
| Concentration | 0.1 µg of NGF (25µL) plus 100 µL PBS /dose | |
| Incubation time | Twice-weekly topical treatments with 0.1 µg of NGF (25µL) plus 100 µL PBS through 7-hour collagen shields for 8 weeks. | |
| Tissue permeability (value with units) | The average subbasal tubulin positive nerve bundle area in controls was 0.85. Treatment with NGF produced significant differences with respect to the control (P < 0.05). | |
| Tissue Sample | Rabbit eye | |
| Ex vivo/In vivo/In vitro | in vivo | |
| STRUCTURE |
| |
| SMILES | N.A. | |